Analyzing China SXT Pharmaceuticals (NASDAQ:SXTC) and Nuvation Bio (NYSE:NUVB)

China SXT Pharmaceuticals (NASDAQ:SXTCGet Rating) and Nuvation Bio (NYSE:NUVBGet Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Insider and Institutional Ownership

2.2% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.2% of Nuvation Bio shares are owned by institutional investors. 34.8% of Nuvation Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares China SXT Pharmaceuticals and Nuvation Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
China SXT Pharmaceuticals N/A N/A N/A
Nuvation Bio N/A -15.33% -14.79%

Analyst Ratings

This is a summary of recent ratings and recommmendations for China SXT Pharmaceuticals and Nuvation Bio, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals 0 0 0 0 N/A
Nuvation Bio 0 2 2 0 2.50

Nuvation Bio has a consensus target price of $4.00, suggesting a potential upside of 100.00%. Given Nuvation Bio’s higher probable upside, analysts clearly believe Nuvation Bio is more favorable than China SXT Pharmaceuticals.

Volatility and Risk

China SXT Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Earnings & Valuation

This table compares China SXT Pharmaceuticals and Nuvation Bio’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
China SXT Pharmaceuticals $2.60 million 0.50 -$5.74 million N/A N/A
Nuvation Bio N/A N/A -$86.85 million ($0.50) -4.00

China SXT Pharmaceuticals has higher revenue and earnings than Nuvation Bio.

Summary

China SXT Pharmaceuticals beats Nuvation Bio on 5 of the 9 factors compared between the two stocks.

About China SXT Pharmaceuticals

(Get Rating)

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.

About Nuvation Bio

(Get Rating)

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.